Idera Pharmaceuticals, Inc. Bouncing on Phase 2 Success

Idera's strugging stock was partially redeemed by good Phase II trial results in psoriasis. The moderate efficacy left investors unenthused, but Idera is touting its candidate as more than just another psoriasis drug, but a potential first-in-class contender in cancer and autoimmune disease.

Apr 1, 2014 at 6:30PM

Idera Pharmaceuticals' (NASDAQ:IDRA) stock market rollercoaster ride left it partially recovered from its 25% plunge just over a week ago upon FDA approval of a competing product developed by Celgene (NASDAQ:CELG). Idera's plaque psoriasis candidate, IMO-8400, gave good results for safety and efficacy in a phase 2 trial, but the stock remains at half mast, as investors are unconvinced by Idera's story in a marketplace crowded with psoriasis options.

Phase 2 good but not great
Idera ran its double-blind, placebo-controlled phase 2 trial in 32 patients with moderate-to-severe plaque psoriasis with a primary goal of showing safety and tolerability of IMO-8400 with 12 weeks of treatment. The secondary endpoint was efficacy as measured by Psoriasis Area and Severity Index (PASI).

All three dose levels of the drug were safe and well-tolerated, which is an absolute necessity to be really competitive in the psoriasis market. Currently available therapies include steroids, topical retinoids, vitamin D derivatives, immune suppressants, and TNF-α inhibitors like Amgen and Pfizer's Enbrel. Those therapies carry some significant risks, however, such as kidney failure for the retinoids and cancer for some of the TNF-α inhibitors. A competitive opportunity exists, then, for a therapy that is shown to be safer. By that standard, IMO-8400 so far passes with flying colors.

However, the PASI scores, while good, are not all that might have been hoped for. PASI is a composite of the redness, thickness, and scaling of psoriasis over several regions of the body. In the trial, nine out of 20 patients, or 45%, achieved a 50% reduction (PASI-50), compared to only one out of seven patients in the placebo group. Only four patients, or 20%, achieved a stricter standard, 75% PASI reduction (PASI-75).

Additional clinical results in an expansion cohort of 12 patients based in the Netherlands are due in a couple of months.

No apples to apples comparison
While that certainly indicates some efficacy (in, admittedly, a small sample), it falls short of higher hopes based on an earlier study that handed in PASI improvements in the 35% to 90% range, and it appears weak compared to Celgene's results for newly approved Otezla, which achieved a 33% PASI-75 score with 16 weeks of treatment in the ESTEEM 1 study and 29% in the ESTEEM 2 study.

Although it would have been great for Idera to knock it out of the park with a really high PASI-75 score, ultimately the important takeaway for efficacy is that in this small trial the drug appeared effective and is worth further study. For a number of reasons, numbers are only roughly comparable from one clinical trial to the next and one drug to the next, so lacking a direct, head-to-head trial, it's hard to say which is superior, the drug with 20% PASI-75 after 12 weeks of treatment (IMO-8400) or the drug with a 29%-33% PASI-75 score after 16 weeks of treatment. This is especially true given the small sample size for the IMO-8400 trial.

A proof of concept for TLR antagonists
A successful psoriasis drug could have potential for a billion or more in annual sales, based on Celgene's guidance of up to $2 billion for Otezla. But Idera views its trial results as more than a test of the drug's potential in plaque psoriasis. IMO-8400 is Idera's lead candidate in the class of Toll-like receptor (TLR) 7, 8, and 9 antagonists. In addition to psoriasis, Idera is planning to develop IMO-8400 in genetically defined forms of B-cell lymphoma and orphan autoimmune diseases.

The company views the recently completed phase 2 trial as a proof-of-concept for TLR antagonists in autoimmune disease, and as such it may herald more successful drug candidates in more indications in the future. So the trial success suggests that IMO-8400 might not only be a significant player in the plaque psoriasis market, but a first-in-class therapy in cancer and orphan disease if it can continue to perform in clinical trials.

3 stocks poised to be multi-baggers
The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have found multi-bagger stocks time and again. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.

Catherine Shaffer has no position in any stocks mentioned. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information